Evolutionary adaptation in fucosyllactose uptake systems supports bifidobacteria-infant symbiosis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31489370.
- Also identified by DOI 10.1126/sciadv.aaw7696 and PMC identifier 6713505.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The human gut microbiota established during infancy has persistent effects on health. In vitro studies have suggested that human milk oligosaccharides (HMOs) in breast milk promote the formation of a bifidobacteria-rich microbiota in infant guts; however, the underlying molecular mechanism remains elusive. Here, we characterized two functionally distinct but overlapping fucosyllactose transporters (FL transporter-1 and -2) from <i>Bifidobacterium longum</i> subspecies <i>infantis</i>. Fecal DNA and HMO consumption analyses, combined with deposited metagenome data mining, revealed that FL transporter-2 is primarily associated with the bifidobacteria-rich microbiota formation in breast-fed infant guts. Structural analyses of the solute-binding protein (SBP) of FL transporter-2 complexed with 2'-fucosyllactose and 3-fucosyllactose, together with phylogenetic analysis of SBP homologs of both FL transporters, highlight a unique adaptation strategy of <i>Bifidobacterium</i> to HMOs, in which the gain-of-function mutations enable FL transporter-2 to efficiently capture major fucosylated HMOs. Our results provide a molecular insight into HMO-mediated symbiosis and coevolution between bifidobacteria and humans.
Medical subject headings
- Bifidobacterium
- Gastrointestinal Microbiome
- Oligosaccharides
- Symbiosis
- Trisaccharides